Curbstone Financial Management Corp lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% in the first quarter, Holdings Channel.com reports. The fund owned 10,616 shares of the company’s stock after selling 400 shares during the quarter. Curbstone Financial Management Corp’s holdings in Eli Lilly and were worth $1,983,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Eli Lilly and by 51.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock valued at $2,042,017,000 after acquiring an additional 4,082,728 shares during the last quarter. Norges Bank acquired a new stake in Eli Lilly and during the 4th quarter valued at $1,463,293,000. Janus Henderson Group PLC raised its stake in Eli Lilly and by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock valued at $1,034,108,000 after purchasing an additional 302,296 shares during the period. Fisher Asset Management LLC raised its stake in Eli Lilly and by 7.7% during the 4th quarter. Fisher Asset Management LLC now owns 5,037,790 shares of the company’s stock valued at $850,580,000 after purchasing an additional 359,479 shares during the period. Finally, California Public Employees Retirement System raised its stake in Eli Lilly and by 2.5% during the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock valued at $772,504,000 after purchasing an additional 110,280 shares during the period. Institutional investors own 75.59% of the company’s stock.
Eli Lilly and stock traded up $0.52 during mid-day trading on Thursday, hitting $182.84. 17,311 shares of the company’s stock were exchanged, compared to its average volume of 4,374,581. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27. The stock has a market cap of $175.34 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $129.21 and a 1-year high of $218.00. The stock has a 50 day moving average of $195.68 and a two-hundred day moving average of $171.39.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Thursday, January 28th. The company reported $2.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm had revenue of $7.44 billion for the quarter, compared to the consensus estimate of $7.27 billion. During the same period in the prior year, the business posted $1.73 earnings per share. The business’s quarterly revenue was up 21.7% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 7.56 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total transaction of $39,053,700.00. Following the completion of the sale, the insider now directly owns 110,807,418 shares in the company, valued at $20,606,855,525.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 555,284 shares of company stock valued at $106,132,302 over the last 90 days. Corporate insiders own 0.09% of the company’s stock.
Several analysts have issued reports on the stock. Bank of America boosted their target price on shares of Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, January 22nd. Mizuho boosted their target price on shares of Eli Lilly and from $222.00 to $228.00 and gave the company a “buy” rating in a research note on Monday, February 1st. Truist boosted their target price on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Cowen upped their price target on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a research note on Friday, February 12th. Finally, Truist Securities upped their price target on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, March 22nd. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $193.88.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: Basic Economics creates winners and losers
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.